Dr. Chandrika Gowda is a board-certified hematologist/oncologist who has strong commitment to research in childhood cancer, including leukemia and neuroblastoma. Her major research project is to study Role of Ikaros tumor suppressor and pro-oncogenic casein Kinase II(CK2) in leukemogenesis and drug resistance. Dr.Gowda's current work is focused on targeting CK2 for treatment of hematological malignancies.

Her most notable work, published in Blood in 2015, established the novel approach of using specific CK2 inhibitors for treatment of high-risk B cell lineage leukemia using PDX models. She has presented her work at various national and international scientific forums and gained national recognition as an outstanding young investigator.

Dr. Gowda's research is currently supported by several extramural grants. She has also authored several chapters and review articles related to leukemia, CK2 and Ikaros. Her other projects are focused on designing novel therapeutic strategies for treatment of high risk neuroblastoma, which is the most common abdominal solid tumor in young children, with poor prognosis.